(Q36916873)

17 August 2017

1 reference

title

Advances in the development of hormonal modulators for the treatment of benign prostatic hyperplasia (English)

1 reference

17 August 2017

Atul Tiwari

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

Expert Opinion on Investigational Drugs

17 August 2017

published in

1 reference

17 August 2017

volume

16

1 reference

17 August 2017

issue

9

1 reference

17 August 2017

page(s)

1425-1439

1 reference

Benign prostatic hyperplasia: an insight into current investigational medical therapies

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Localization by in situ hybridization of steroid 5alpha-reductase isozyme gene expression in the human prostate and preputial skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

5α-Reductase Type 1 Immunostaining is Enhanced in Some Prostate Cancers Compared With Benign Prostatic Hyperplasia Epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Prostate cancer prevention trial yields positive results, but with a few cautions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Antiandrogens: selective androgen receptor modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Gonadotropin-releasing hormone receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor-expressing pituitary cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Gonadotropin-releasing hormone and its analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Management of urinary retention due to benign prostatic hyperplasia using luteinizing hormone-releasing hormone agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Effects on the endocrine system of long-term treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Development of GnRH antagonists for prostate cancer: new approaches to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Luteinizing hormone-releasing hormone agonist effects on skeletal muscle: how hormonal therapy in prostate cancer affects muscular strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

An evidence-based approach to understanding the pharmacological class effect in the management of prostatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Gonadotropin-releasing-hormone-receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Safety of GnRH agonists and antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Controlled ovarian hyperstimulation in assisted reproduction: effect on the immune system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

GnRH antagonists in the treatment of gynecological and breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Oxytocin, oxytocin-associated neurophysin and the oxytocin receptor in the human prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Oxytocin: a paracrine regulator of prostatic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

The oxytocin receptor antagonist atosiban inhibits cell growth via a "biased agonist" mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Identification, localization and functional in vitro and in vivo activity of oxytocin receptor in the rat penis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Induction of apoptosis in human prostate stromal cells by 4-hydroxytamoxifen: an alternative therapy for benign prostate hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Human bladder as a novel target for vitamin D receptor ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

Current and emerging investigational medical therapies for the treatment of overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1425

10.1517/13543784.16.9.1425

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference